Hadar Levy - BrainsWay VP COO

BRSYF Stock  USD 8.53  0.00  0.00%   

Insider

Hadar Levy is VP COO of BrainsWay
Age 49
Phone972 2 582 4030
Webhttps://www.brainsway.com

BrainsWay Management Efficiency

The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2021) %, meaning that it generated substantial loss on money invested by shareholders. BrainsWay's management efficiency ratios could be used to measure how well BrainsWay manages its routine affairs as well as how well it operates its assets and liabilities.
BrainsWay has accumulated 754 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. BrainsWay has a current ratio of 7.56, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BrainsWay until it has trouble settling it off, either with new capital or with free cash flow. So, BrainsWay's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BrainsWay sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BrainsWay to invest in growth at high rates of return. When we think about BrainsWay's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Asa HillstenBICO Group AB
48
Chad ClouseAurora Spine
N/A
Erik GatenholmBICO Group AB
34
Hector MartinezBICO Group AB
38
Mikael EngblomBICO Group AB
46
Karin DanielssonBICO Group AB
41
Artur AiraBICO Group AB
56
David MeyerAurora Spine
N/A
Niclas EmanuelssonBICO Group AB
52
Richard GinnTenon Medical
58
Jason CliftonBICO Group AB
N/A
Itedale RedwanBICO Group AB
N/A
Trent NorthcuttAurora Spine
56
Lotta BusBICO Group AB
53
Laszlo GaramszegiAurora Spine
52
Erica BellBICO Group AB
50
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people. BrainsWay [BRSYF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

BrainsWay Leadership Team

Elected by the shareholders, the BrainsWay's board of directors comprises two types of representatives: BrainsWay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrainsWay. The board's role is to monitor BrainsWay's management team and ensure that shareholders' interests are well served. BrainsWay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrainsWay's outside directors are responsible for providing unbiased perspectives on the board's policies.
Menachem Esq, Gen VP
Christopher Jako, Pres CEO
Avner Hagai, Founder and President and Director
Christopher Boyer, VP Marketing
Hadar Levy, VP COO
Yiftach Roth, Founder, Chief Scientist and Director
Moria Ankri, VP RD
Aron Tendler, Chief Officer
Pr Zangen, Member CoFounder
Richard Areglado, VP CFO

BrainsWay Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BrainsWay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in BrainsWay Pink Sheet

When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Please note, there is a significant difference between BrainsWay's value and its price as these two are different measures arrived at by different means. Investors typically determine if BrainsWay is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BrainsWay's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.